StartsideAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
11,66 $
Etterbørs:(0,00 %)0,00
11,66 $
Stengt: 22. nov., 20:00:00 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Forrige sluttkurs
11,66 $
Dagsintervall
11,53 $ - 12,22 $
Årsintervall
10,41 $ - 19,09 $
Markedsverdi
1,12 mrd. USD
Gjennomsnittlig volum
1,35 mill.
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Omsetning | 50,02 mill. | 613,22 % |
Driftskostnader | 44,20 mill. | 5,21 % |
Nettoomsetning | −2,62 mill. | 92,76 % |
Netto resultatmargin | −5,25 | 98,98 % |
Fortjeneste per aksje | −0,03 | 92,68 % |
EBITDA | 708,00k | 102,05 % |
Faktisk avgiftssats | −3,47 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 65,81 mill. | −57,04 % |
Totale aktiva | 158,25 mill. | −22,08 % |
Totale passiva | 83,59 mill. | −10,07 % |
Total egenkapital | 74,66 mill. | — |
Utestående aksjer | 96,36 mill. | — |
P/B-forhold | 14,95 | — |
Avkastning på aktiva | −0,52 % | — |
Avkastning på kapital | −0,73 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | −2,62 mill. | 92,76 % |
Kontantstrøm fra drift | −6,89 mill. | 81,98 % |
Kontanter fra investering | 4,93 mill. | −49,80 % |
Kontanter fra finansiering | 1,18 mill. | −96,14 % |
Netto kontantstrøm | −265,00k | −114,51 % |
Fri kontantstrøm | −9,99 mill. | 64,96 % |
Om
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Administrerende direktør
Grunnlagt
1990
Nettsted
Ansatte
154
